{"groups":[{"description":"Participants received sugemalimab (CS1001) 1200 mg intravenously every 3 weeks (Q3W)","id":"FG000","title":"R/R ENKTL"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"14"}],"type":"Adverse Event"},{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"40"}],"type":"Lack of Efficacy"},{"reasons":[{"groupId":"FG000","numSubjects":"10"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Dosing delayed over 9 weeks"},{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Achieved CR and completed 2 years of treatment"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"80"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"13"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"67"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}]}